REVISED HEALTH WORKERS HANDBOOK

ON

PANDEMIC INFLUENZA A(H1N1) 2009
“SWINE FLU”

Developed by:
The National Institute for Communicable Diseases (NICD)
of the National Health Laboratory Service (NHLS)

In collaboration with:
The South African National Department of Health
and World Health Organisation (WHO)

Revised Version 2
Last updated: 22 July 2009
1. Background on pandemic influenza A(H1N1) 2009 ................................................................. 3
   1.1 What is pandemic influenza A(H1N1) 2009 virus? ................................................................. 3
   1.2 Transmission ........................................................................................................................... 3
   1.3 Typical signs and symptoms of infection .................................................................................. 3
   1.4 Public health concerns about the new virus ............................................................................. 3
   1.5 Recent changes in South Africa .............................................................................................. 3

2. Case definitions for identification of pandemic influenza A(H1N1) 2009 ................................ 4
   2.1 ILI (Influenza Like Illness) – Mild Disease: ........................................................................... 4
   2.2 SARI (Severe Acute Respiratory Infection) – Moderate to Severe Disease: ......................... 4
   2.3 Features of severe illness ....................................................................................................... 4

3. Who should be tested? .................................................................................................................. 5
   3.1 Laboratories conducting testing ............................................................................................ 5
   3.2 Step-by-step guide for specimen collection, storage and transportation .............................. 5
   3.3 Additional information about specimen collection ............................................................... 6
   3.4 Swabs and Viral transport medium (VTM) ............................................................................ 6
   3.5 Individuals at high risk for serious complications of influenza ............................................. 6

4. Case Management & Infection Control ..................................................................................... 7
   4.1 Mild cases ............................................................................................................................... 7
   4.2 Moderate to severe cases ....................................................................................................... 7
   4.3 Treatment .............................................................................................................................. 7
   4.4 Prophylaxis .......................................................................................................................... 8
   4.5 Pregnant Women .................................................................................................................. 9
   4.6 Adverse events and contraindications .................................................................................. 9

5. Who to contact details if you have questions? .......................................................................... 9

Appendix 1: Home Care Guidance: Doctors/Nurses directions to Patients/Parents ...................... 10
Appendix 2: WHO Patient Care Checklist .................................................................................. 11
1. Background on pandemic influenza A(H1N1) 2009

1.1 What is pandemic influenza A(H1N1) 2009 virus?
This is a new influenza A (H1N1) virus that has never before circulated among humans. This virus is not related to previous or current human seasonal influenza viruses. It has also been called “swine flu” and “novel flu”.

1.2 Transmission
The virus is spread from person-to-person. It is transmitted as easily as the normal seasonal flu and can be passed to other people by exposure to infected droplets expelled by coughing or sneezing that can be inhaled, or that can contaminate hands or surfaces. To prevent spread, people who are ill should cover their mouth and nose when coughing or sneezing, stay home when they are unwell, clean their hands regularly, and keep some distance from healthy people, as much as possible.

1.3 Typical signs and symptoms of infection
Signs of pandemic influenza A(H1N1) 2009 are flu-like, including: fever, cough, headache, muscle and joint pain, sore throat and runny nose, and sometimes vomiting and diarrhoea.

1.4 Public health concerns about the new virus
Seasonal influenza occurs every year and the viruses change each year - but many people have some immunity to the circulating virus which helps limit infections. South Africa also uses seasonal influenza vaccines to reduce illness and deaths. But pandemic influenza A/H1N1 2009 is a new virus and one to which most people have no or little immunity and, therefore, this virus could cause more infections than are seen with seasonal flu.

The new pandemic influenza virus appears to be as contagious as seasonal influenza, and is spreading fast particularly among young people (from ages 10 to 45). The severity of the disease ranges from very mild symptoms to severe illnesses that can result in death. The majority of people who contract the virus experience the milder disease and recover without antiviral treatment or medical care. Of the more serious cases, more than half of hospitalized people had underlying health conditions or weak immune systems. The overall severity of the influenza pandemic has been assessed to be moderate.

1.5 Recent changes in South Africa
It is now clear that the pandemic virus has been established throughout the country, and that sustained community transmission is inevitable. Moving forward, a strategy that concentrates on the detection, laboratory confirmation, and investigation of all cases, including those with mild illness, is extremely resource-intensive thus leaving little capacity for the monitoring and management of severe cases. In addition it diverts limited resources away from managing other diseases such as HIV and TB. In line with a World Health Organization (WHO) recommendation, it has now been decided to stop routine laboratory testing of all suspected cases of pandemic influenza infection.
2. Case definitions for identification of pandemic influenza A(H1N1) 2009

The symptoms of pandemic influenza are non-specific and may be similar to seasonal influenza infections. The case definitions below will enable you to recognise a case that may be infected with pandemic influenza, and classify them into one of two categories:

2.1 ILI (Influenza Like Illness) – Mild Disease:
- An individual with recent onset of an influenza-like illness (ILI), which may include fever ≥38°C PLUS ONE OR MORE of the following acute respiratory symptoms (sore throat, rhinorrhoea / nasal congestion, cough or other signs part of the respiratory complex, myalgia, diarrhoea).

2.2 SARI (Severe Acute Respiratory Infection) – Moderate to Severe Disease:
- Persons 2 days to < 3 months old:
  - Any child with diagnosis of suspected sepsis or physician diagnosed lower respiratory tract infection (LRTI) irrespective of signs and symptoms. Patient presenting within 7 days of the onset of illness.
- ≥ 3 months old to < 5 years old:
  - Any child ≥ 3 months to < 5 years with physician-diagnosed acute lower respiratory infection (LRTI) including bronchiolitis, pneumonia, bronchitis and pleural effusion. Patient presenting within 7 days of the onset of illness.
- ≥ 5 years old:
  - Any person presenting with: sudden onset of fever (>38°C) AND cough or sore throat AND shortness of breath, or difficulty breathing with or without clinical or radiographic findings of pneumonia. Patient presenting within 7 days of the onset of illness.

2.3 Features of severe illness

The criteria for severe pneumonia according to the WHO integrated management of childhood illness (IMCI) guidelines are below:
- Any child age 2 months up to 5 years with:
  - Cough or difficult breathing, AND with
  - Any general danger signs (unable to drink or breast-feed, vomits everything, convulsions, lethargy or unconsciousness), OR
  - Chest indrawing or stridor in a calm child.

Severity criteria in adults of any age group include: respiratory distress, dyspnoea, hypotension and / or evidence of hypoxia.

Although data on the spectrum of illness is limited with pandemic influenza A(H1N1) 2009 clinicians should expect complications to be similar to those seen with seasonal influenza and will include: exacerbation of underlying chronic medical conditions, upper respiratory tract disease (sinusitis, otitis media, croup), lower respiratory tract disease (pneumonia, bronchiolitis), cardiac (myocarditis, pericarditis), musculoskeletal (myositis, rhabdomyolysis), neurologic (acute and post infectious encephalopathy- encephalitis and febrile seizures), and secondary bacterial pneumonia.
3. Who should be tested?

As of 16 July 2009, the laboratory testing strategy has been modified to only conduct testing if a clinical decision warrants these investigations. Laboratory testing of mild illness (patients who fit the ILI case definition) is NOT recommended, as it provides very little advantage to the clinical management of individual patients. Furthermore, NICD will no longer be conducting routine laboratory testing of all suspected or probable cases for pandemic influenza. However, there is still an ongoing need in all countries to closely monitor unusual events, such as clusters of cases of severe or fatal H1N1 infection, clusters of respiratory illness requiring hospitalization, or unexplained or unusual clinical patterns associated with serious or fatal cases.

Therefore, testing is only recommended for the following patients:

- Patients who meet the SARI case definition (i.e. severe infections) where a laboratory diagnosis will assist in patient management or patients hospitalised due to a lower-respiratory infection, and where no other explanation for illness is indicated and influenza forms part of the differential diagnosis.
- Patients with co-morbid disease and at risk for serious complications (as per list under point 3.5) and who are symptomatic with SARI or ILI should be considered for testing if it will guide clinical management.
- Clusters of cases where a diagnosis of the cause of the outbreak is needed.
- An individual who has died where pandemic influenza A(H1N1) is suspected as the cause of death.

*NB* These recommendations for laboratory testing do not apply to surveillance activities managed by the NICD (e.g. Viral-watch, SARI surveillance, etc.). Please continue testing as guided by those individual surveillance programmes.

3.1 Laboratories conducting testing

Laboratory testing capabilities are currently in a process of being decentralized from NICD towards diagnostic laboratories throughout the country. Private sector laboratories have begun to offer in-house diagnostic services for patients seen at private sector health facilities whilst, testing of patients attended to by public sector healthcare facilities will soon be conducted by selected NHLS sites, NICD will continue to support both sectors. Until such time as these systems have been implemented. However, the NICD will begin to focus on enhanced clinical and virological surveillance at specific sites around the country.

Private sector patients: Patients seen at private sector healthcare facilities should be tested at private sector laboratories, in accordance with these guidelines. Please discuss with your individual laboratory about the requirements and recommendations for testing, as well the cost implications to the patient/medical aid.

Public sector patients: The NICD and the Virology Department of the University of Stellenbosch at Tygerberg Hospital (for patients within Western Cape Province), will continue to provide diagnostic support for patients seen at public sector health facilities, until such time that this is available within the NHLS. Note, testing will be offered as a diagnostic service, and therefore will be charged for at a standard rate. Costs associated with testing may vary between laboratories and over time, therefore please consult that laboratory prior sending the specimens.

3.2 Step-by-step guide for specimen collection, storage and transportation

1. Put on appropriate personal protective equipment including a mask (N95 mask if available) and surgical gloves (specimen collection poses a risk of aerosol production).
2. Swab each nostril with one swab. Swab the throat using a second swab. (Use only Dacron or Rayon swabs. Wooden swabs are not suitable for testing).
3. Place both swabs together into a container of viral transport medium (VTM).
4. Wrap the container (containing VTM and swabs) in absorbent material (e.g. cotton wool).
5. Place in a secondary container (preferably sturdy plastic or stainless steel) with a well fitting lid.
6. Wrap again in absorbent material and place in a third container (e.g. a cooler box) containing ice (specimens and VTM must be transported at 4°C).
7. Put the patient details on the OUTSIDE of this container including:
   - Patient Name,
- Health facility (where appropriate),
- Doctor and contact numbers,
- Lab name and contact person, and
- Attach a copy of any investigation forms / specimen slips that have been completed.

8. Transport specimens directly to appropriate laboratory for patients seen at your health facility (see section 3.1).

Specimens to be tested at the NICD should be sent to the following address:
Dhamari Naidoo
National Influenza Unit, National Institute for Communicable Diseases (NICD)
1 Modderfontein Road
Sandringham, Johannesburg, 2131
South Africa

3.3 Additional information about specimen collection
- Specimens for virus isolation or for detection of viral nucleic acids or antigens should be taken preferably during the first three days after onset of clinical symptoms, but may be taken up to a week after onset, or even later in severely ill or immunocompromised patients or children under 12 years of age.
- Specimens should preferably be taken prior to commencement of antivirals.
- Nasopharyngeal swabs may be collected instead of nose and throat swabs. Swabs pose a lower risk of infection for staff than do nasopharyngeal aspirates (NPA) or nasal washes, both of which may generate aerosols.
- In addition to swabs from the upper respiratory tract, invasive procedures such as bronchoalveolar lavage or lung biopsy can be performed for the diagnosis of virus infections of the lower respiratory tract where clinically indicated.
- Post mortem samples may also be submitted.

3.4 Swabs and Viral transport medium (VTM)
- Wooden swabs are not suitable for respiratory virus PCR. Please use Dacron or Rayon swabs.
- All specimens must be transported in viral transport medium (VTM) as instructed above.
- The appropriate swabs and viral transport medium may be obtained from your usual local laboratory. Public sector health practitioners should contact their local NHLS laboratory. Private sector practitioners should contact their usual private laboratory.
- Local laboratories should stock VTM and the appropriate swabs, which may be obtained through your usual supplier. For further information on VTM and swabs contact the National Influenza Centre (Amelia Buys/Cardia Fourie, 011 386 6373).

3.5 Individuals at high risk for serious complications of influenza
1. Persons (adults or children) with underlying medical conditions and who are receiving regular medical care for conditions such as chronic pulmonary disease (including asthma) and cardiac disease (excluding hypertension), chronic renal and hepatic diseases, diabetes mellitus and similar metabolic disorders
2. Individuals who are immunosuppressed (including HIV infected persons and persons on immunosuppressive medications);
3. Adults and children who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration;
4. All persons over the age of 65 years;
5. Children and adolescents who are receiving long-term aspirin therapy and who might be at risk for experiencing Reye’s syndrome after influenza virus infection;
6. Residents of nursing homes and other chronic-care facilities
7. Pregnant women (see section 4.5)
4. Case Management & Infection Control

4.1 Mild cases

- Mild cases do NOT require confirmatory laboratory testing and should NOT be admitted to hospital. They should be advised to isolate themselves at home for 7 days after the onset of symptoms and managed symptomatically.
- Supportive care at home is adequate for recovery. Provide the patient with advice which should include: resting, drinking plenty of fluids and keeping warm and dry. Use a pain reliever for head and muscle aches. Non-aspirin pain relievers should be used by children and young adults due to the risk of Reye’s syndrome.
- Antiviral medication is NOT recommended for mild cases or contacts not at risk for development of severe disease unless these patients are at high risk for serious complications of influenza.
- Patients at high risk for serious complications of influenza should be offered antiviral therapy at the discretion of the attending physician.
- The patient and their contacts should be given infection control guidance as follows:
  o Regular hand washing with soap and water
  o Cover nose and mouth with a tissue when coughing and sneezing (or use the upper part of your sleeve). Dispose of used tissues in a dustbin, and then wash hands with soap and water.
- Contacts of cases should stay at home at the first sign of illness and follow guidelines as above. They should seek medical care only if required.

4.2 Moderate to severe cases

- Cases with moderate to severe illness (based on a clinical assessment) that require hospital admission should be managed as follows:
  o Where possible these cases should be isolated in their own room with the door closed for the duration of hospital stay. If discharged prior to day 7 of onset of illness, they can complete home isolation as outlined above.
  o Droplet and contact precautions should be instituted.
  o Health workers should wear a properly fitting N95 mask on entry into the patient’s room (if available).
  o The patient should wear a standard surgical mask whenever he/she is required to leave the isolation room.
  o Where separate isolation rooms are not available, suspected cases should be cohorted in a designated ward and the above precautions instituted.
  o Oseltamivir should be used for treatment of moderate to severe cases (see section 4.3)

4.3 Treatment

Use of antiviral agents should be limited to persons with the following indications:

- Individuals with moderate or severe influenza-related illness, OR
- Any individual at high risk for serious complications of influenza and in whom treatment can be commenced within 2 days of onset of illness.

The pandemic influenza A(H1N1) 2009 virus is currently sensitive (susceptible) to the neuraminidase inhibitor antiviral medications zanamivir and oseltamivir. It is resistant to the adamantane antiviral medications, amantadine and rimantadine. Note that recommendations for use of antivirals may change as data on antiviral susceptibilities become available. Oseltamivir (Tamiflu®) and zanamivir (Relenza®) are neuraminidase inhibitor (NI) antivirals registered for use in South Africa and active against influenza A and B viruses. Oseltamivir (Tamiflu®) is orally administered and is registered for use in individuals aged ≥1 year of age. Zanamivir (Relenza®) is administered through an inhaler and is registered for use in individuals aged ≥ 12 year of age.

Antiviral treatment with zanamivir or oseltamivir should be initiated as soon as possible after the onset of symptoms. Although benefit is likely to be greatest when therapy is initiated within 48 hours, some benefit may still be obtained in patients whose therapy is started later in the course of illness. Recommended duration of treatment is five days. Antiviral doses recommended for treatment of pandemic influenza A(H1N1) 2009 virus infection in adults or children 1 year of age or older are similar to those for seasonal influenza and are described in Table 1.
Table 1: Recommended dosage of antiviral agents for treatment of confirmed, probable or suspected pandemic influenza A(H1N1) 2009 cases*

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Weight</th>
<th>Oseltamivir dosage*</th>
<th>Zanamivir dosage*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>75 mg twice per day</td>
<td>Two 5 mg inhalations (10 mg total) twice per day</td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 kg or less</td>
<td>30 mg twice per day</td>
<td>Two 5 mg inhalations (10 mg total) twice per day</td>
<td></td>
</tr>
<tr>
<td>15–23 kg</td>
<td>45 mg twice per day</td>
<td>Two 5 mg inhalations (10 mg total) twice per day (only in children aged 12 years or older)</td>
<td></td>
</tr>
<tr>
<td>24–40 kg</td>
<td>60 mg twice per day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;40 kg</td>
<td>75 mg twice per day</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Recommended duration of treatment is 5 days. Oseltamivir is not currently licensed for use in <1 year old and zanamivir is only registered for children ≥ 12 years of age.

In addition to antiviral medications, other therapeutics to treat complications should be utilized where indicated (e.g. antibiotics for bacterial complications, e.g. pneumonia). Supportive care is also advised depending on the clinical severity of disease (oxygen therapy, mechanical ventilation, etc.).

Table 1: Summary of clinical management of pandemic influenza A(H1N1) 2009 virus infection

<table>
<thead>
<tr>
<th>Modalities</th>
<th>Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>In case of pneumonia, empiric treatment for community acquired pneumonia (CAP) per published guidelines pending microbiologic results (e.g. 2-3 days); tailored therapy thereafter if pathogen(s) identified.</td>
</tr>
<tr>
<td>Antiviral therapy</td>
<td>Only indicated for individuals with moderate to severe disease, and individual at risk for development of severe disease. The pandemic influenza A(H1N1) 2009 virus is currently resistant to amantadine and rimantadine.</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Moderate to high dose steroids are NOT recommended. They are of unproven benefit and potentially harmful.</td>
</tr>
<tr>
<td>Infection control</td>
<td>Standard plus Droplet Precautions. For aerosol-generating procedures use particulate respirator (N95, FFP2 or equivalent), eye protection, gowns, gloves,..</td>
</tr>
<tr>
<td>NSAIDS, antipyretics</td>
<td>Paracetamol can be administered for fever. Avoid administration of salicylates (aspirin and aspirin containing products) in children and young adults (&lt; 18 years old) due to risk of Reye’s syndrome.</td>
</tr>
<tr>
<td>Oxygen therapy</td>
<td>Monitor oxygen saturation and maintain SaO2 over 90% (95% for pregnant women) with nasal cannulae or face mask.</td>
</tr>
</tbody>
</table>

4.4 Prophylaxis

Antiviral post-exposure prophylaxis should only be offered to high risk close contacts of suspected or confirmed cases of infection due to pandemic influenza A(H1N1) 2009 (see section 3.5). Dosage of agents for antiviral prophylaxis is described in Table 2. Duration of antiviral chemoprophylaxis post-exposure is 10 days after the last known exposure to an ill confirmed case.

Table 3: Recommended dosage of antiviral agents for prophylaxis of high risk contacts of confirmed, probable or suspected pandemic influenza A(H1N1) 2009 cases*

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Weight</th>
<th>Oseltamivir dosage*</th>
<th>Zanamivir dosage*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>75 mg once per day</td>
<td>Two 5 mg inhalations (10 mg total) once per day</td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 kg or less</td>
<td>30 mg once per day</td>
<td>Two 5 mg inhalations (10 mg total) once per day (only in children aged 12 years or older)</td>
<td></td>
</tr>
<tr>
<td>15–23 kg</td>
<td>45 mg once per day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24–40 kg</td>
<td>60 mg once per day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;40 kg</td>
<td>75 mg once per day</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Recommended duration of prophylaxis is 10 days. Oseltamivir is not currently licensed for use in <1 year old and zanamivir is only registered for children ≥ 12 years of age.
4.5 Pregnant Women

No clinical studies have been conducted to assess the safety of these antiviral for pregnant women. Because of the unknown effects of these drugs on pregnant women and their fetuses, oseltamivir or zanamivir should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus; the manufacturers’ package inserts should be consulted. However, no adverse effects have been reported among women who received oseltamivir or zanamivir during pregnancy or among infants born to women who have received oseltamivir or zanamivir. Pregnancy should not be considered a contraindication to oseltamivir or zanamivir use. Because zanamivir is an inhaled medication and has less systemic absorption, some experts prefer zanamivir over oseltamivir for use in pregnant women when feasible.

4.6 Adverse events and contraindications

Clinicians should consult manufacturers’ package inserts for further information on adverse events and contraindications for these agents.

5. Who to contact details if you have questions?

Answers to most questions are available on the following websites:

- NICD Website: www.nicd.ac.za
- Department of Health Website: www.doh.gov.za/swineflu/swineflu-f.html
- World Health Organisation Website: www.who.int/csr/disease/swineflu/en/
- Centers for Disease Control and Prevention (CDC, Atlanta): www.cdc.gov/h1n1flu/

Further questions can be address to:

- Daytime NICD Influenza Hotline (8am to 5pm Monday to Friday) - 082 477 8026
- After-hours, weekends and public holidays – NICD Hotline - 082 883 9920
Appendix 1: Home Care Guidance: Doctors/Nurses directions to Patients/Parents

Home Care Guidance: Doctors/Nurses directions to Patients/Parents

1. You will probably be sick for several days with fever and respiratory symptoms.

2. Take Medications as Prescribed:
   - Take all of the antiviral medication as directed (where applicable).
   - Continue to cover your cough and wash your hands often (even when taking antiviral medications), to prevent spreading influenza to others.
   - Call the clinic/GP if you (or your child) experience any side effects; i.e. nausea, vomiting, rash, or unusual behaviour.
   - Take medications for symptom relief as needed for fever and pain such as paraectamol or ibuprofen. These medicines do not need to be taken regularly if your symptoms improve.
   - Do not give aspirin (acetylsalicylic acid) or products that contain aspirin to children or teenagers 18 years old or younger.
   - Children younger than 4 years of age should not be given over-the-counter cold medications without first speaking with a health care provider.

3. Seek Emergency Care:
   If your child experiences any of the following:
   - Fast breathing or trouble breathing
   - Bluish or grey skin colour
   - Not drinking enough fluids
   - Severe or persistent vomiting
   - Not waking up or not interacting
   - Being so irritable that the child does not want to be held
   - Flu-like symptoms improve but then return with fever and worse cough

   In adults, emergency warning signs that need urgent medical attention include:
   - Difficulty breathing or shortness of breath
   - Pain or pressure in the chest or abdomen
   - Sudden dizziness
   - Confusion
   - Severe or persistent vomiting
   - Flu-like symptoms improve but then return with fever and worse cough

4. Follow These Home Care Recommendations:
   - Stay home for 7 days after your symptoms begin or until you have been symptom-free for 24 hours, whichever is longer.
   - Drink clear fluids (such as water, broth, sports drinks, electrolyte beverages for infants) to keep from being dehydrated.
   - Dishes can be done with hot soapy water.
   - Throw away tissues and other disposable items used by the sick person in the trash. Wash your hands after touching used tissues and similar waste.
   - Have everyone in the household wash hands often with soap and water, especially after coughing or sneezing. Alcohol-based hand cleaners are also effective.
   - Avoid touching your eyes, nose and mouth. Germs spread this way.
   - Continue with medication for chronic diseases as prescribed (e.g. ART).
Appendix 2: WHO Patient Care Checklist

New influenza A (H1N1) June 2009

Replaces: 15 May 2009
Expires: December 2009.

UPON ARRIVAL TO CLINICAL SETTING/Triage
- Direct patient with flu-like symptoms to designated waiting area
- Provide instruction and materials to patient on respiratory hygiene/cough etiquette
- Put medical/surgical mask on patient if available and tolerable to patient

UPON INITIAL ASSESSMENT
- Record respiratory rate over one full minute and oxygen saturation if possible
- If respiratory rate is high or oxygen saturation is below 90% alert senior care staff for action
- Record history, including flu-like symptoms, date of onset, travel, contact with people who have flu-like symptoms, comorbidities
- Consider specialized diagnostic tests (e.g., RT-PCR)
- Use medical/surgical mask, eye protection, gloves when taking respiratory samples
- Label specimen correctly and send as per local regulations with biohazard precautions
- Consider alternative or additional diagnoses
- Report suspected case to local authority

BEFORE PATIENT TRANSFER/TRANSFER
- Put medical/surgical mask on patient if available and tolerable to patient

BEFORE EVERY PATIENT CONTACT
- Put on medical/surgical mask
- Clean hands
- Put on eye protection, gown and gloves if there is risk of exposure to body fluids/splashes
- Clean and disinfect personal/dedicated patient equipment between patients
- Change gloves (if applicable) and clean hands between patients

IF USING AEROSOL-GENERATING PROCEDURES ALSO (e.g., intubation, bronchoscopy, CPR, suction)
- Allow entry of essential staff only
- Put on gown
- Put on particulate respirator (e.g., EU FFP2, US NIOSH-certified N95) if available
- Put on eye protection, and then put on gloves
- Perform planned procedure in an adequately ventilated room

BEFORE ENTERING DESIGNATED AREA (Isolation room or cohort)
- Put on medical/surgical mask
- Clean hands

BEFORE LEAVING DESIGNATED AREA (Isolation room or cohort)
- Remove any personal protective equipment (gloves, gown, mask, eye protection)
- Dispose of disposable items as per local protocol
- Clean hands
- Clean and disinfect dedicated patient equipment and personal equipment that has been in contact with patient
- Dispose of viral-contaminated waste as clinical waste

BEFORE DISCHARGE OF CONFIRMED OR SUSPECTED CASE
- Provide instruction and materials to patient/caregiver on respiratory hygiene/cough etiquette
- Provide advice on home isolation, infection control and limiting social contact
- Record patient address and telephone number

INITIAL AND ONGOING PATIENT MANAGEMENT
Supportive therapy for new influenza A (H1N1) patient as for any influenza patient including:
- Give oxygen to maintain oxygen saturation above 90% or if respiratory rate is elevated (when oxygen saturation monitor not available)
- Give paracetamol/acetaminophen if considering an antipyretic for patients less than 18 years old
- Give appropriate antibiotic if evidence of secondary bacterial infection (e.g., pneumonia)
- Consider alternative or additional diagnoses
- Decide on need for antivirals* (oseltamivir or zanamivir), considering contra-indications and drug interactions

BEFORE PATIENT ENTRY TO DESIGNATED AREA (Isolation room or cohort)
- Post restricted entry and infection control signs
- Provide dedicated patient equipment if available
- Ensure at least 1 metre (3.3 feet) between patients in cohort area
- Ensure local protocol for frequent linen and surface cleaning in place

This checklist is not intended to be comprehensive. Additions and modifications to fit local practice are encouraged.

This checklist is intended for use by hospital staff treating anyone with a medically suspected or confirmed case of new influenza A (H1N1) per local definition. This checklist highlights areas of care critical for the management of new influenza A (H1N1). It is not intended to replace routine care.

*See instructions on the back side for additional information and references. Equipment on this checklist is recommended if available.
ABOUT THIS CHECKLIST

The WHO Patient Care Checklist: new influenza A (H1N1) is intended for use by hospital staff treating a patient with a medically suspected or confirmed case of new influenza A (H1N1). This checklist combines two aspects of care: (i) clinical management of the individual patient and (ii) infection control measures to limit the spread of new influenza A (H1N1).

WHO Patient Safety Checklists are practical and easy-to-use tools that highlight critical actions to be taken at vulnerable moments of care. They are produced in a format that can be referred to readily and repeatedly by staff to help ensure that all essential actions are performed. WHO Patient Safety Checklists are not comprehensive protocols and are not intended to replace routine care.

How to use the checklist

Staff can use this checklist in a variety of ways - ticking the boxes is optional. The objective is to ensure that no critical patient care items are missed during or immediately following care.

The checklist can be:
- used as part of the patient's clinical record;
- reproduced as wall posters for hospitals or clinics; or
- printed up as cards for staff members to carry around with them.

Parts of the checklist can also be extracted for use in any of these formats.

This checklist does not replace clinical guidance or clinical judgment. Its users should also familiarize themselves with the relevant WHO guidance documents referenced below, which were used in the development of the checklist.

Local modification

The WHO Patient Care Checklist: new influenza A (H1N1) may be reformatted or revised to accommodate local practice.

Facilities and individuals are cautioned, however, against making the checklist too complex.

Related guidance

Guidance relating to infection control:

Infection prevention and control in health care in providing care for confirmed or suspected A (H1N1) swine influenza patients interim guidance (Publication date: 29 April 2009) http://www.who.int/csr/resources/publications/infection_control/index.html


Guidance relating to clinical management:


* Currently there are a lack of data on the clinical effectiveness of antivirals for this disease. Antiviral drugs are to be used according to national pandemic influenza preparedness plans. If antivirals are prescribed, oseltamivir or zanamivir should be used for influenza A (H1N1) patients because of increased risk of the resistance with other antivirals. Where antiviral drugs are available for treatment, clinicians should make decisions based on assessment of the individual patient's risk. Risks versus benefits should also be evaluated on a case-by-case basis.

Such guidance may be updated as the situation evolves. For the most up-to-date guidance on the checklist and other documents, refer to the WHO website (www.who.int) or contact your WHO country office.

GLOSSARY OF SELECTED CHECKLIST TERMS

Clean hands: Hands can be cleaned either by handwashing with soap and water or by handrubbing with an alcohol-based handrub formulation. The preferred technique while caring for suspected or confirmed cases of new influenza A (H1N1) is handrubbing, unless hands are visibly soiled. Hands must be cleaned at five key moments: 1) before touching a patient; 2) before clean/aseptic procedure; 3) after body fluid exposure risk; 4) after touching a patient; and 5) before touching patient surroundings.

Designated area (isolation room / cohort): The placing of patients either colonized or infected with the same pathogen in one designated area. It is specifically used when single or isolation rooms are not available. It allows for identified health-care workers to provide care to these specific patients with the aim of trying to prevent spread of infection to others. Patients with confirmed infection should ideally be in a separate cohort to those with suspected infection.

Cough etiquette: Health-care workers, patients and family members should cover mouth and nose (e.g. with a tissue) when coughing or sneezing. If a tissue is used, discard it in a bin with a lid and then clean hands. Cough etiquette should be communicated to patients through posters and leaflets.

Separate waiting area: Waiting area for symptomatic persons should be separate from general waiting area. This can be a separate part of the general waiting area as long as there is at least one metre (3.3 feet) distance between the designated area and the regular waiting area. Maintain at least one metre between symptomatic patients within this designated area.

Eye protection: This can either be an eye visor, goggles, or a face shield. Conventional eye glasses are not designed to protect against splashes to eye mucosa and should not be used as eye protection.

Flu-like symptoms: Fever, cough, headache, muscle and joint pain, sore throat, runny nose, and sometimes vomiting and diarrhoea.

Gown: A clean, non-sterile long-sleeved gown.

Infection control guidance to patient/caregiver on discharge: If patient still symptomatic or if patient less than one year old (infants less than one year old may continue to be infectious for three weeks after cessation of symptoms):

- Patient quarantined: the sick person should be placed in a separate room and should have limited social contact.
- Instruction on cough etiquette.
- All persons in the household should perform hand hygiene frequently and after every contact with the sick person.
- The caregiver should wear the best available protection to prevent exposure to respiratory secretions, and avoid contact with body fluids or contaminated items; minimize close interaction (less than 1 metre) and face-to-face contact with the patient; perform hand hygiene when indicated.

Medical/surgical masks: Procedure or surgical masks to protect the wearer's nose and mouth from inadvertent exposures (e.g. splashed).

Particulate respirator: A special type of fit-tested mask with the capacity to filter particles to protect against inhaling infectious aerosols (e.g. EU FP2 and US NIOSH-certified N95).

Respiratory hygiene: See cough etiquette.

RESPIRATORY RATE (reference for high values):

<table>
<thead>
<tr>
<th>AGE</th>
<th>RESPIRATORY RATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;2 months</td>
<td>&gt;60 at minute</td>
</tr>
<tr>
<td>2–11 months</td>
<td>&gt;50 at minute</td>
</tr>
<tr>
<td>1–5 years</td>
<td>&gt;40 at minute</td>
</tr>
<tr>
<td>&gt;5–12 years</td>
<td>&gt;30 at minute</td>
</tr>
<tr>
<td>&gt;13 years</td>
<td>&gt;20 at minute</td>
</tr>
</tbody>
</table>

CHECKLIST DEVELOPMENT PROCESS

In response to the pandemic threat by a new influenza A (H1N1) strain, the checklist development process began on 30 April 2009. The checklist development group in the WHO Patient Safety Programme collaborated with technical experts in WHO Health Security and Environment. They consulted experts in three areas: i) infection control, ii) clinical management of pandemic-prone influenza, and iii) health care checklists. The design and content of the checklist were developed iteratively through successive rounds of consultation. Clinical teams in a number of settings tested its clarity and usability. Its use in clinical practice will be the subject of ongoing evaluation.